CAR-Modified CD4+ and CD8+ T Cells for Durable Tumor Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The efficacy of cultured T cells, particularly cloned CD8+ T cells, is frequently limited by their failure to persist after adoptive transfer in clinical immunotherapy due to differentiation into short-lived cytolytic effector cells during in vitro culture.
Innovation Solution
The use of genetically modified CD4+ T cells with chimeric antigen receptors that confer and augment the ability of CD8+ T cells to sustain anti-tumor reactivity and increase tumor-specific proliferation, combined with CD8+ T cells expressing chimeric antigen receptors specific for antigens associated with the disease or disorder.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cloned CD8+ T cells are used for adoptive immunotherapy, then tumor-specific cytolytic activity is improved, but in vivo persistence and survival are worsened due to differentiation into short-lived effector cells
Solution Approach 1:
The patent introduces CD4+ T cells as intermediary helper cells that support the survival and persistence of CD8+ T cells in vivo. These CD4+ T cells provide cytokine support and immunological assistance that enables CD8+ T cells to maintain their anti-tumor reactivity longer without differentiating into short-lived effector cells, thus resolving the contradiction between immediate cytolytic activity and long-term persistence
2Productivity
If genetically modified T cells are used to enhance anti-tumor reactivity, then tumor-specific proliferation is improved, but complexity of cell preparation and genetic modification is worsened
Solution Approach 1:
The patent employs chimeric antigen receptors (CARs) that can be genetically introduced into both CD4+ and CD8+ T cells to target the same tumor antigen. This universal approach allows both cell types to recognize and respond to the same tumor target, enabling coordinated anti-tumor activity while using a standardized genetic modification strategy that reduces overall preparation complexity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific CD8+ T cells in the presence of tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment a CD8+ T cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific CD8+ T cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.